SAHA | Scientist.com

DESCRIPTION

SAHA is a potent reversible pan-histone deacetylase inhibitor, including both class I and class II HDACs. It functions by binding to the active site of histone deacetylases and acting as a chelator of Zinc ions. SAHA is used to halt the growth of transformed cells, induce apoptosis in T cell lymphoma, and arrest cancer cell growth.

DETAILS

Purity: ≥98%
Synonyms: Vorinostat, Zolinza, suberoylanilide hydroxamic acid, Suberanilohydroxamic acid
Cas Number: 149647-78-9
References: Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., ... & Frankel, S. R. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109(1), 31-39. Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature biotechnology, 25(1), 84-90. Shankar, S., Davis, R., Singh, K. P., Kurzrock, R., Ross, D. D., & Srivastava, R. K. (2009). Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Molecular cancer therapeutics, 8(6), 1596-1605.
Application: FA
Formulation: Crystalline solid
Chemical Name: N'-hydroxy-N-phenyloctanediamide
Molecular Weight: 264.3
Molecular Formula: C14H20N2O3
Storage Conditions: Product should be kept at -20°C.
Pubchem Openeye Can Smiles: C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO